An advocacy group criticizes Hims & Hers Health for allegedly misleading Super Bowl ad promoting weight loss products, violating FDA regulations. Read more here.

JPMorgan lowered the firm’s price target on Novo Nordisk (NVO) to DKK 1,000 from DKK 1,050 and keeps an Overweight rating on the ...

Telehealth company Hims & Hers Health (HIMS) recently stirred up controversy with its ad promoting its compounded weight-loss drugs aired ...

The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...

Trademark prosecution data reveals how the rival healthcare companies are ensuring exclusivity internationally for their ...